Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshimitsu Fujii

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Inflammatory Bowel Diseases|April 13, 2011
Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's diseaseSea Bong Hyun, Yoshio Kitazume, Masakazu Nagahori, et al.
Alimentary Pharmacology & Therapeutics|July 29, 2021
Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's diseaseKento Takenaka, Ami Kawamoto, Shuji Hibiya, et al.
Journal of Gastroenterology and Hepatology|October 3, 2023
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesXiang Gao, Toshimitsu Fujii, Byong Duk Ye, et al.
Digestion|December 6, 2025
Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor- Related ColitisRyo Morikawa, Toshimitsu Fujii, Akiko Tamura, et al.
Intestinal Research|July 10, 2026
Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North studyTadakazu Hisamatsu, Toshimitsu Fujii, Hiroshi Nakase, et al.
Alimentary Pharmacology & Therapeutics|March 1, 2021
Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remissionMiyuki Kaneshiro, Kento Takenaka, Kohei Suzuki, et al.
BMC Gastroenterology|May 5, 2022
Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn's diseaseShuji Hibiya, Kazuo Ohtsuka, Kento Takenaka, et al.
Gastroenterology|February 16, 2020
Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative ColitisKento Takenaka, Kazuo Ohtsuka, Toshimitsu Fujii, et al.
The American Journal of Gastroenterology|December 26, 2022
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's DiseaseKento Takenaka, Yoshio Kitazume, Ami Kawamoto, et al.
Inflammatory Intestinal Diseases|May 4, 2026
Leucine-Rich Alpha-2 Glycoprotein Is an Accurate Serum Marker for Endoscopic and Histological Remission in Ulcerative ColitisAmi Kawamoto, Toshimitsu Fujii, Shohei Tanaka, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Inflammatory Bowel Diseases|April 13, 2011
Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's diseaseSea Bong Hyun, Yoshio Kitazume, Masakazu Nagahori, et al.
Alimentary Pharmacology & Therapeutics|July 29, 2021
Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's diseaseKento Takenaka, Ami Kawamoto, Shuji Hibiya, et al.
Journal of Gastroenterology and Hepatology|October 3, 2023
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesXiang Gao, Toshimitsu Fujii, Byong Duk Ye, et al.
Digestion|December 6, 2025
Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor- Related ColitisRyo Morikawa, Toshimitsu Fujii, Akiko Tamura, et al.
Intestinal Research|July 10, 2026
Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North studyTadakazu Hisamatsu, Toshimitsu Fujii, Hiroshi Nakase, et al.
Alimentary Pharmacology & Therapeutics|March 1, 2021
Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remissionMiyuki Kaneshiro, Kento Takenaka, Kohei Suzuki, et al.
BMC Gastroenterology|May 5, 2022
Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn's diseaseShuji Hibiya, Kazuo Ohtsuka, Kento Takenaka, et al.
Gastroenterology|February 16, 2020
Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative ColitisKento Takenaka, Kazuo Ohtsuka, Toshimitsu Fujii, et al.
The American Journal of Gastroenterology|December 26, 2022
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's DiseaseKento Takenaka, Yoshio Kitazume, Ami Kawamoto, et al.
Inflammatory Intestinal Diseases|May 4, 2026
Leucine-Rich Alpha-2 Glycoprotein Is an Accurate Serum Marker for Endoscopic and Histological Remission in Ulcerative ColitisAmi Kawamoto, Toshimitsu Fujii, Shohei Tanaka, et al.
Pageof 9